ABTL-0812 is an orally bioavailable lipid analog that inhibits mTORC1, mTORC2, and dihydrofolate reductase (DHFR), with potential antineoplastic activity. By targeting mTORC1 and mTORC2, it induces apoptosis and reduces tumor cell proliferation.
Usually ships within 24 hours.